SANUWAVE Q2 revenue $4.7M (+20% YoY); net loss $7.3M; guides Q3 growth 15-25%

SANUWAVE Health, Inc.

2023-Q2 EPS reported -$0.04 revenue$8,450,000

Q2 revenue $4.7M (+20% YoY) within 15-25% guidance; H1 revenue $8.5M (+19%).
Gross margin improved to 74% from 72%; operating income $0.9M with $1.25M one-time expense reversal.
Net loss $7.3M vs net income $1.6M in Q2 2022 due to non-cash derivative liability losses.
Q3 2023 revenue growth guidance 15-25% YoY; inventory constraints expected to ease in Q4.
Recent: CEO Morgan Frank (May), President Andrew Walko (July), $3M asset-backed notes issued.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 1.0

SANUWAVE Health, Inc. reported second quarter ended June 30, 2023 results: revenue $4.7 million, net income $7.3 million. Guidance reaffirmed.

Period: second quarter ended June 30, 2023
Revenue: $4.7 million
Net income: $7.3 million
Guidance: reaffirmed
Result: reported results

Exact text from the filing

wound care products, today announced its 2nd quarter 2023 results. For the three months ended June 30, 2023: ■ Revenue for the three months ended June 30, 2023 totaled $4.7 million, an increase of 20%, as compared to $3.9 million for the same period of 2022. This growth falls within the previously provided guidance range of 15-25% for Q2 2023. Revenue for

View on SEC.gov

44 earnings releases filed in the last 30 days. Browse all earnings releases →

SANUWAVE Health, Inc. filing history →

Source: SEC EDGAR

accession 0001140361-23-039308

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.